je.st
news
Tag: designation
RetroSense Therapeutics Granted Orphan Drug Designation For Lead Product RST-001 For Retinitis Pigmentosa
2014-11-05 05:53:53| drugdiscoveryonline Home Page
RetroSense Therapeutics, LLC, a privately-held biopharmaceutical company, announced recently that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation for the Company’s lead product RST-001 for the treatment of retinitis pigmentosa (RP)
Tags: product
lead
drug
granted
Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
2014-10-27 11:45:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of patients with Epidermal Growth Factor Receptor (EGFR) mutation-negative, and Anaplastic Lymphoma Kinase (ALK) rearrangement-negative non-small cell lung cancer (NSCLC) whose disease has progressed on or following platinum-based chemotherapy. Language: English Contact: Media Contacts:Pamela Eisele, 267-305-3558orClaire Mulhearn, 908-236-1118orInvestor Contacts:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
cell
cancer
therapy
Ford's Global Green Brand designation will change automakers' future
2014-10-16 04:23:00| Automakers - Topix.net
In 2014 Ford Motor Company earned the No. 1 spot on Interbrand's 50 Best Global Green Brands list.
Tags: change
future
global
brand
Cree Earns U.S. Department Of Defense Manufacturing Readiness Level 8 Designation
2014-10-02 13:02:52| rfglobalnet Home Page
Cree, Inc., a leader in gallium nitride (GaN) RF devices, has earned the U.S. Department of Defense (DoD) manufacturing readiness level eight (MRL 8) designation.
Tags: level
department
manufacturing
defense
MabVax Therapeutics Receives Orphan Drug Designation For Therapeutic Vaccine To Treat Childhood Cancer Neuroblastoma
2014-10-01 14:02:11| drugdiscoveryonline Home Page
MabVax Therapeutics Holdings, Inc. (OTCQB: TELKD), a clinical stage oncology drug development company, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's vaccine intended for the treatment of the childhood cancer neuroblastoma
Tags: drug
cancer
treat
receives
Sites : [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] next »